Welcome to the Department of Cellular Therapy which is home to one of Europe’s biggest and most modern GMP facilities for cellular products.

  Dag Josefsen, MD PhD, Head of Department

(Group leaders: E.M. Inderberg and S. Wälchli) has the capacity to undertake complete pre-clinical studies for immunotherapeutic molecules such as vaccines and adoptive T cell transfer (TCR, CAR). It possesses the competence to deliver molecular biology products isolated from patient material (TCR), to perform cellular assays and in vivo animal studies. Finally, innovative tools are also developed in collaboration with academy and private companies.

The Immunomonitoring Lab (Head: E.M. Inderberg) is a heritage from the former research group of Prof. G. Gaudernack and was included in the Department of Cellular Therapy in 2012. It participated to both academic and industrial trials, more information can be found here. 

Our labs are located at the Oslo Cancer Cluster Incubator OCCI

ACT-centre aims at facilitating the development of novel advanced therapy medicinal products (ATMP) and make novel therapies available to Norwegian patients. More information can be found here. 

PROGRAM (program with additional speakers will be released by August 15, 2025) 

Welcome by Moderators & Co-Chairs

Else Marit Inderberg, PhD, Unit Leader, Translational Research Unit, Section for Cell Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway

&

Tuva Holt Hereng, PhD, Senior Manager R&D Cell Therapy, Oslo, Norway

Speaker 

Development of CAR-Treg therapies to modulate immune responses in transplantation and autoimmunity
Nathalie Belmonte, PhD, Senior VP Research and Technical Development, Quell Therapeutics

Solving CAR-T Manufacturing and QC Challenges with Structured Support and Strategic Solutions
Anna Pasetto, PhD, Associate Professor, Director of Center for Advanced Cell Therapy (ACT), Oslo University Hospital, Norway

Automated manufacturing of CAR effector cells: From viral to non-viral gene transfer
Ulrike Kohl, MD, PhD, Institute Director / University Professor, Institute of Clinical Immunology, Medical Faculty, University of Leipzig and Fraunhofer Institute for Cell Therapy and Immunology, Germany.

Maximizing the Innate Power of NK cells in cancer therapy
Ebba Sohlberg, PhD, Researcher and Project Manager at the Center for Infectious Medicine, Karolinska Institutet, Sweden

Additional speakers will be confirmed and updated here.

NOTE about a workshop the next day:

On October 9, 2025, 9am-5pm at OCC Innovation Park: You are invited to register your interest to join a specialized workshop conducted by Thermo Fisher Scientific. Please register your interest with corinna.pohl@thermofisher.com, who will contact you early Q3 2025 about the program.

All news